{"id":1341,"date":"2015-10-15T01:32:37","date_gmt":"2015-10-14T23:32:37","guid":{"rendered":"http:\/\/lupusgalicia.org\/?p=1341"},"modified":"2015-10-15T02:03:11","modified_gmt":"2015-10-15T00:03:11","slug":"lupus-viena-2015-lupus-review","status":"publish","type":"post","link":"https:\/\/lupusgalicia.org\/?p=1341","title":{"rendered":"Lupus Viena 2015. Lupus Review"},"content":{"rendered":"<h1 style=\"text-align: center;\"><span style=\"color: #993366;\"><em>El<\/em><strong> Dr.<\/strong><em><em><strong> Jaime Calvo Al\u00e9n,<\/strong>\u00a0experto en el \u00e1mbito de las enfermedades autoinmunes sist\u00e9micas ha realizado\u00a0estos r<\/em>es\u00famenes de lo m\u00e1s destacado del \u201c11th International Congress on Systematic Lupus Erythematosus\u201d, en Viena 2015 para Lupus Review.<\/em><\/span><\/h1>\n<p><em>LUPUS REVIEW es una iniciativa de la Sociedad Espa\u00f1ola de Reumatolog\u00eda, que ha contado con la colaboraci\u00f3n de GSK. Estos v\u00eddeos recogen las principales novedades del Congreso sobre Investigaci\u00f3n b\u00e1sica y patog\u00e9nesis, cl\u00ednica, tratamiento y otros aspectos.<\/em><\/p>\n<h4 style=\"text-align: center;\"><span style=\"color: #ff0000;\"><em><strong>CL\u00cdNICA<\/strong><\/em><\/span><\/h4>\n<p><a href=\"http:\/\/www.lupusreview.ser.es\/videos.php\">Ver v\u00eddeo Lupus review: Cl\u00ednica<\/a><\/p>\n<p style=\"text-align: center;\"><em><strong>\u00a0I.-\u00a0<\/strong><\/em><em><strong><u>Afectaci\u00f3n Hematol\u00f3gica ponencia realizada por el\u00a0<\/u><\/strong><\/em><em><strong><u>Dr Isemberg<\/u><\/strong><\/em><\/p>\n<ul>\n<li><em>ANEMIA<\/em>\n<ul>\n<li><em>Mecanismos:<\/em>\n<ul>\n<li><em>Auto-anticuerpos (AHAI)<\/em><\/li>\n<li><em>Aumento de Hepcidina (Inhibe ferroportina)<\/em><\/li>\n<li><em>Anticuerpos antiEPO<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>Recomendaciones de tratamiento AHAI<\/em>\n<ul>\n<li><em>1\u00ba Corticoides a dosis altas (3 semanas)<\/em><\/li>\n<li><em>2\u00ba TRX (AZA, CFX, Danazol&#8230;)<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>NEUTROPENIA<\/em>\n<ul>\n<li><em>Mecanismos:<\/em>\n<ul>\n<li><em>Redistribuci\u00f3n<\/em><\/li>\n<li><em>Destrucci\u00f3n perif\u00e9rica<\/em><\/li>\n<li><em>Infecciones ?<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>Tratamiento<\/em>\n<ul>\n<li><em>&lt;1000:esteroides<\/em><\/li>\n<li><em>&lt;500 Estimulador de colonias<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>LINFOPENIA: medidas profil\u00e1cticas &lt;400<\/em><\/li>\n<li><em>TROMBOCITOPENIA: Tratamiento &lt;20.000<\/em><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<ul>\n<li><em><strong>Estudio RAPS (Rivaroxaban en APS)<\/strong><\/em>\n<ul>\n<li><em>Objetivo primario: no inferior a Warfarina en anticoagulaci\u00f3n (test de generaci\u00f3n de trombina, TGT)<\/em><\/li>\n<li><em>Objetivo secundario: eficacia cl\u00ednica y seguridad<\/em><\/li>\n<li><em>Abierto, aleatorizado (42 d\u00edas, extensi\u00f3n a 180 d\u00edas); 116 pacientes<\/em><\/li>\n<li><em>Resultados<\/em>\n<ul>\n<li><em>Inferior a la warfarina en el TGT<\/em><\/li>\n<li><em>Mejor en el tiempo de alcanzar el pico de trombina<\/em><\/li>\n<li><em>Similar en niveles de marcadores de coagulaci\u00f3n<\/em><\/li>\n<li><em>Eficacia cl\u00ednica; No trombosis<\/em><\/li>\n<li><em>Seguridad: No sangrados<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em><strong>Conclusiones<\/strong><\/em>\n<ul>\n<li><em>Los datos sugieren que el Rivaroxban no es inferior en el tratamiento del SAF tromb\u00f3tico.<\/em><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: center;\"><em><strong><u>II.- Afectaci\u00f3n Pulmonar intervenci\u00f3n de la\u00a0<\/u><\/strong><\/em><em><strong><u>Dra Mosca<\/u><\/strong><\/em><\/p>\n<ul>\n<li><em>Neumonitis aguda (5-10%)<\/em>\n<ul>\n<li><em>Asociada a brote agudo y ac.anti-Ro<\/em><\/li>\n<li><em>50% evolucionan a EPID cr\u00f3nica<\/em><\/li>\n<li><em>Tto: Esteroides, CFX, e IGIV<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>EPID cr\u00f3nica (15%)<\/em>\n<ul>\n<li><em>Aparece en enfermedad tard\u00eda (15%)<\/em><\/li>\n<li><em>Cl\u00ednica insidiosa<\/em><\/li>\n<li><em>Tto: Esteroides, AZA, CFX, RTX<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>Pulm\u00f3n encogido (11%)<\/em>\n<ul>\n<li><em>Asociado a ac. anti-RNP y anti-Ro; Tto: Esteroides<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>Hemorragia pulmonar (2-4%): Plasmaf\u00e9resis<\/em><\/li>\n<li><em>HAP (0.5-11%): Asociado a ac RNP\/APS<\/em><\/li>\n<li><em>Ideas finales:<\/em>\n<ul>\n<li><em>Relativamente frecuente<\/em><\/li>\n<li><em>Descartar infecciones siempre<\/em><\/li>\n<li><em>Atenci\u00f3n a s\u00edntomas leves<\/em><\/li>\n<li><em>Tratamiento temprano<\/em><\/li>\n<li><em>Asociaciones con ac anti-Ro, anti-RNP, APS<\/em><\/li>\n<li><em>Medidas preventivas de infecciones<\/em><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: center;\"><em><strong><u>III.- Prevenci\u00f3n osteoporosis realizada\u00a0por el\u00a0<\/u><\/strong><\/em><em><strong><u>Dr Urowitz<\/u><\/strong><\/em><\/p>\n<ul>\n<li><em>Prevalencia de baja DMO: 31,5%<\/em>\n<ul>\n<li><em>Pre-menop\u00e1usicas: 17,3%<\/em><\/li>\n<li><em>Post-menop\u00e1usicas:<\/em>\n<ul>\n<li><em>Baja DMO: 43,2%<\/em><\/li>\n<li><em>Osteoporosis : 12,3%<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>Hombres<\/em>\n<ul>\n<li><em>&lt;50 a\u00f1os: 27,3%<\/em><\/li>\n<li><em>&gt;50 a\u00f1os:<\/em>\n<ul>\n<li><em>Baja DMO: 80%<\/em><\/li>\n<li><em>Osteoporosis: 10%<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>Fracturas sintom\u00e1ticas: 11.1% (solo 50% baja DMO)<\/em><\/li>\n<li><em>Factores asociados a baja DMO<\/em>\n<ul>\n<li><em>Edad: descenso de 6&amp; por a\u00f1o<\/em><\/li>\n<li><em>Dosis acumulada de esteroides: descenso 4% por gramo<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>Evoluci\u00f3n DMO<\/em>\n<ul>\n<li><em>40% de los pacientes empeoran<\/em><\/li>\n<li><em>Factores asociados:<\/em>\n<ul>\n<li><em>Edad<\/em><\/li>\n<li><em>Actividad cl\u00ednica<\/em><\/li>\n<\/ul>\n<\/li>\n<li><em>Prevenci\u00f3n (esteroides &gt;7,5 mg; &gt;3 meses)<\/em>\n<ul>\n<li><em>Calcio y vitamina D siempre<\/em><\/li>\n<li><em>DMO baja: Biofosfonatos<\/em><\/li>\n<li><em>Alto riesgo: considerar Forsteo<\/em><\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<h4 style=\"text-align: center;\"><span style=\"color: #ff0000;\"><em><strong>INVESTIGACI\u00d3N B\u00c1SICA Y PATOG\u00c9NESIS<\/strong><\/em><\/span><\/h4>\n<p><a href=\"http:\/\/www.lupusreview.ser.es\/videos.php\">Ver v\u00eddeo de Investigaci\u00f3n b\u00e1sica y patog\u00e9nesis<\/a><\/p>\n<p style=\"text-align: center;\"><strong><u>IV.- LES y muerte celular del\u00a0<\/u><\/strong><strong><u>Dr Hormann<\/u><\/strong><\/p>\n<p>APOPTOSIS<\/p>\n<ul>\n<li>El aclaramiento del material apopt\u00f3pico est\u00e1 alterado en el LES<\/li>\n<li>N\u00facleos apopt\u00f3picos NO digeridos se visualizan en centros germinales en LES<\/li>\n<li>Este material permite la perpetuaci\u00f3n de CB autoreactivas que pueden salir a periferia<\/li>\n<li>En periferia C\u00e9lulas Necr\u00f3ticas Secundarias exponen Ag de material apopt\u00f3pico<\/li>\n<li>Las CB autoreactivas producen AC frente a esos Ags<\/li>\n<li>Reacci\u00f3n inflamatoria<\/li>\n<\/ul>\n<p>NETOSIS<\/p>\n<ul>\n<li>Red de material nuclear neutrof\u00edlico con mol\u00e9culas t\u00f3xicas<\/li>\n<li>Fisiol\u00f3gicamente existen mecanismos de degradaci\u00f3n<\/li>\n<li>En el LES esto est\u00e1 limitado:\n<ul>\n<li>Anticuerpos bloqueantes frente a las enzimas que lo degradan<\/li>\n<li>Anticuerpos frente a la estructura reticular<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: center;\"><strong><u>V.- Se\u00f1alando a la celula B por el\u00a0<\/u><\/strong><strong><u>Dr Shlomchik<\/u><\/strong><\/p>\n<ul>\n<li>La c\u00e9lula B como iniciadora de la respuesta autoinmune<\/li>\n<li>Sustituye a la c\u00e9lula dendr\u00edtica<\/li>\n<li>Estudios en modelos animales:\n<ul>\n<li>Auto-Ag: activaci\u00f3n T independiente del BCR v\u00eda TLR<\/li>\n<li>Funci\u00f3n de la prote\u00edna de membrana MyD88 (adaptador del TLR)<\/li>\n<li>La CB activada autoreactiva estimula con la CT<\/li>\n<li>Demostraci\u00f3n de que est\u00e1 por encima de la CD:\n<ul>\n<li>Delecci\u00f3n del MyD88 en la CB detiene la enfermedad<\/li>\n<li>Delecci\u00f3n del MyD88 en la CD no tiene efectos<\/li>\n<\/ul>\n<\/li>\n<li>La CD pudiera tener un efecto pontenciador intra\u00f3rgano.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: center;\"><strong><u>VI.- C\u00e9lulas B reguladoras del\u00a0<\/u><\/strong><strong><u>Dr C. Mauri<\/u><\/strong><\/p>\n<p>C\u00e9lulas B reguladoras (CD19 CD24 CD38)<\/p>\n<ul>\n<li>Producen IL10 (inmunosupresor)<\/li>\n<li>Suprimen la diferenciaci\u00f3n de la c\u00e9lula T<\/li>\n<li>En el LES estas funciones est\u00e1n disminuidas<\/li>\n<li>Este defecto parece reversible; el tratamiento con RTX lo revierte parcialmente<\/li>\n<\/ul>\n<p style=\"text-align: center;\"><strong><u>VII. C\u00e9lulas B &amp; Plasm\u00e1ticas \u00a0del\u00a0<\/u><\/strong><strong><u>Dr R.Voll<\/u><\/strong><\/p>\n<p>Activaci\u00f3n CB<\/p>\n<p>CT \u00a0\u21d4CB \u2192Plasmoblasto \u2192CP<\/p>\n<p>C\u00e9lula plasm\u00e1tica<\/p>\n<ul>\n<li>Supervivencia corta<\/li>\n<li>supervivencia larga<\/li>\n<\/ul>\n<p>CP de supervivencia larga<\/p>\n<ul>\n<li>Responsable del LES refractario<\/li>\n<li>No eliminadas por terapias convencionales y RTX<\/li>\n<li>Est\u00e1n sobre representadas en ri\u00f1\u00f3n en NL<\/li>\n<li>Las CP renales producen x10 auto-ac que otras CP<\/li>\n<li>Sensibles a los inhibidores proteos\u00f3micos<\/li>\n<\/ul>\n<h4 style=\"text-align: center;\"><strong><span style=\"color: #ff0000;\">TRATAMIENTO<\/span><\/strong><\/h4>\n<p><a href=\"http:\/\/www.lupusreview.ser.es\/videos.php\">Ver v\u00eddeo de Tratamiento<\/a><\/p>\n<p style=\"text-align: center;\"><strong><u>VIII.- BORTEZOMID de\u00a0<\/u><\/strong><strong><u>Dr Voll<\/u><\/strong><\/p>\n<ul>\n<li>Proteosomas\n<ul>\n<li>Complejo proteico para eliminar proteinas con fallos de producci\u00f3n<\/li>\n<li>CP producen 8000 mol\u00e9culas\/segundo<\/li>\n<li>Su inhibici\u00f3n conduce a la apoptosis<\/li>\n<\/ul>\n<\/li>\n<li>Bortezomid\n<ul>\n<li>Inhibidor de proteosomas<\/li>\n<li>Aprobado para el MM y el linfoma del manto<\/li>\n<li>Elimina CP de supervivencia larga<\/li>\n<\/ul>\n<\/li>\n<li>Resultados en modelos animales\n<ul>\n<li>Reducci\u00f3n de c\u00e9lulas productoras de Igs y de anti-DNA<\/li>\n<li>Eliminaci\u00f3n de CD de supervivencia corta y larga<\/li>\n<li>Aumento de la supervivencia<\/li>\n<li>Reducci\u00f3n de CP intra-renales<\/li>\n<\/ul>\n<\/li>\n<li>Resultados en humanos\n<ul>\n<li>Eliminaci\u00f3n de CP de supervivencia corta y larga<\/li>\n<li>Descenso del SLEDAI<\/li>\n<li>Reducci\u00f3n de niveles de anti-DNA y Igs (mantienen niveles protectores)<\/li>\n<li>Aumenta el complemento<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: center;\"><strong><u>IX.-Lupus cut\u00e1neo presentado por el\u00a0<\/u><\/strong><strong><u>Dr A Kuhn<\/u><\/strong><\/p>\n<ul>\n<li>Prevenci\u00f3n: UV, tabaco<\/li>\n<li>Terapia t\u00f3pica:\n<ul>\n<li>Esteroides: t\u00f3pico, interlesional, cura oclusiva<\/li>\n<li>Tacrolimus<\/li>\n<\/ul>\n<\/li>\n<li>1\u00aa L\u00ednea\n<ul>\n<li>Esteroides sist\u00e9micos (lesiones generalizados)<\/li>\n<li>HCQ, si falla\n<ul>\n<li>Monitorizaci\u00f3n<\/li>\n<li>Asociaci\u00f3n de Quinacrina (100mg\/24h)<\/li>\n<\/ul>\n<\/li>\n<li>2\u00aa L\u00ednea\n<ul>\n<li>MTX, MMF, Dapsona (bulloso), Retinoides<\/li>\n<\/ul>\n<\/li>\n<li>3\u00aa L\u00ednea\n<ul>\n<li>Talidomida<\/li>\n<li>Biol\u00f3gicos: Belimumab<\/li>\n<\/ul>\n<\/li>\n<li>F\u00e1rmacos aprobados para otras indicaciones\n<ul>\n<li>Alitretinoin (derivado vit D), aprobado para eccema\n<ul>\n<li>Ester del Ac. Fum\u00e1rico: aprobado para psoriasis<\/li>\n<\/ul>\n<\/li>\n<li>No indicado en lupus cut\u00e1neo: CFX, AZA, CpA<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><strong>X.- Nefritis L\u00fapica: Gu\u00eda EULAR por el\u00a0Dr D Boumpas<\/strong><\/p>\n<p>CRITERIOS DE NO RESPUESTA ADECUADA<\/p>\n<ul>\n<li>Ausencia de mejor\u00eda alguna a los 3-4 meses<\/li>\n<li>Solo respuesta parcial (=50%) a los 6-12 meses<\/li>\n<li>Ausencia de respuesta completa a los 24 meses<\/li>\n<\/ul>\n<p>TIPOS DE ACTUACI\u00d3N<\/p>\n<ul>\n<li>Cambios:\n<ol>\n<li>MMF \u2192 CFX<\/li>\n<li>CFX \u2192 MMF<\/li>\n<\/ol>\n<\/li>\n<\/ul>\n<ul>\n<li>A\u00f1adir anti-calcineur\u00ednico<\/li>\n<li>Sustituir por Rituximab\n<ul>\n<li>Meta-an\u00e1lisis de 300 pacientes refractarios con 70% de respuesta (40% respuesta completa)<\/li>\n<li>Mejores resultados en el brote inicial y en reca\u00eddas<\/li>\n<li>En GNFRP con semilunas parece poco efectivo<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p style=\"text-align: center;\"><strong><u>XI.- Terapias Experimentales por <\/u><\/strong><strong><u>K Derfler y D Farge<\/u><\/strong><\/p>\n<p>INMUNOABSORCI\u00d3N<\/p>\n<p>&#8211; 16 pts refractarios (NL 100%, pulm\u00f3n 44%, SNC 38%)<\/p>\n<table>\n<tbody>\n<tr>\n<td width=\"79\"><span style=\"color: #800080;\">\u00a0<\/span><\/td>\n<td width=\"107\"><span style=\"color: #800080;\">Basal<\/span><\/td>\n<td width=\"103\"><span style=\"color: #800080;\">3M<\/span><\/td>\n<td width=\"99\"><span style=\"color: #800080;\">12M<\/span><\/td>\n<\/tr>\n<tr>\n<td width=\"79\"><span style=\"color: #800080;\">Prot<\/span><\/td>\n<td width=\"107\">9,2<\/td>\n<td width=\"103\">5,1<\/td>\n<td width=\"99\">2,3<\/td>\n<\/tr>\n<tr>\n<td width=\"79\"><span style=\"color: #800080;\">SLEDAI<\/span><\/td>\n<td width=\"107\">19<\/td>\n<td width=\"103\">6<\/td>\n<td width=\"99\">4<\/td>\n<\/tr>\n<tr>\n<td width=\"79\"><span style=\"color: #800080;\">Anti-DNA<\/span><\/td>\n<td width=\"107\">168<\/td>\n<td width=\"103\">119<\/td>\n<td width=\"99\">49<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>&#8211; No infecciones severas<\/p>\n<p>C\u00c9LULAS MADRE MESENQUIMALES<\/p>\n<ul>\n<li>Auto TMO<\/li>\n<li>Infusi\u00f3n alog\u00e9nica de CMM\n<ul>\n<li>M\u00e9dula \u00f3sea<\/li>\n<li>Cord\u00f3n umbilical<\/li>\n<\/ul>\n<\/li>\n<li>Efectos:\n<ul>\n<li>Reguladores: CT, CB, NK, CD (Citoquinas reguladoras)<\/li>\n<li>\u00abHoming\u00bb en \u00e1reas de inflamaci\u00f3n (integrinas de membrana)<\/li>\n<\/ul>\n<\/li>\n<li>Resultados prometedores en modelos animales y en humanos. Ensayo cl\u00ednico en marcha.<\/li>\n<\/ul>\n<p style=\"text-align: center;\"><strong><u>XII.- TRATAMIENTOS EN ESTUDIO<\/u><\/strong><\/p>\n<p>NUEVAS MOL\u00c9CULAS (671 registradas)<\/p>\n<ul>\n<li>Rontalizumab<\/li>\n<li>Sifalimumab<\/li>\n<li>Anifrolumab<\/li>\n<li>Blisimimod<\/li>\n<li>Obinutuzumab<\/li>\n<\/ul>\n<p>ENSAYOS CL\u00cdNICOS EN MARCHA EN NL<\/p>\n<ul>\n<li>CALIBRATE: Tto Secuencial RTX y BLB<\/li>\n<li>BLISS-LN: BLB para NL<\/li>\n<li>RING: RTX en LES refrectario<\/li>\n<li>RITUXILUP: RTX sin corticoides<\/li>\n<li>AURA: Voclosporina<\/li>\n<li>ATLAS: Anti-TWEAK<\/li>\n<li>Abatacept+MMF vs MMF<\/li>\n<\/ul>\n<h4 style=\"text-align: center;\"><span style=\"color: #ff0000;\"><strong>OTROS ASPECTOS<\/strong><\/span><\/h4>\n<p><a href=\"http:\/\/www.lupusreview.ser.es\/videos.php\">Ver v\u00eddeo de Otros aspectos<\/a><\/p>\n<p>Aqu\u00ed el Dr Jaime Calvo Al\u00e9n habla de varias exposiciones importantes entre las que hay que destacar las presentaciones realizadas por RELESSER.<\/p>\n<p style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>XIII.- Diagn\u00f3stico y clasificaci\u00f3n del Dr M. Aringer<\/strong><\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>XIV.- Profilaxis Primaria y Anticuerpos Anti-fosfolip\u00eddicos por el Dr Ricard Cervera<\/strong><\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>XV.- Embarazo y LES por el Dr R. Fischer-Betz<\/strong><\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"text-decoration: underline;\"><strong>XVI.- RELESSER Dirigido por Dr Rua-Figueroa y realizado por varios autores<\/strong><\/span><\/p>\n<p style=\"text-align: center;\">\n","protected":false},"excerpt":{"rendered":"<p>El Dr. Jaime Calvo Al\u00e9n,\u00a0experto en el \u00e1mbito de las enfermedades autoinmunes sist\u00e9micas ha realizado\u00a0estos res\u00famenes de lo m\u00e1s destacado del \u201c11th International Congress on Systematic Lupus Erythematosus\u201d, en Viena 2015 para Lupus Review. LUPUS REVIEW es una iniciativa de la Sociedad Espa\u00f1ola de Reumatolog\u00eda, que ha contado con la colaboraci\u00f3n de GSK. Estos v\u00eddeos [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[21,5],"tags":[45,10,27,38,46],"class_list":["post-1341","post","type-post","status-publish","format-standard","hentry","category-jornadas-y-congresos","category-lupus-internacional","tag-congreso-internacional-lupus","tag-congresos","tag-jornadas-y-congresos-2","tag-mujer-lupica","tag-nuevas-moleculas"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\r\n<title>Lupus Viena 2015. Lupus Review - Asociaci\u00f3n Galega de Lupus<\/title>\r\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\r\n<link rel=\"canonical\" href=\"https:\/\/lupusgalicia.org\/?p=1341\" \/>\r\n<meta property=\"og:locale\" content=\"es_ES\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"Lupus Viena 2015. Lupus Review - Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"og:description\" content=\"El Dr. Jaime Calvo Al\u00e9n,\u00a0experto en el \u00e1mbito de las enfermedades autoinmunes sist\u00e9micas ha realizado\u00a0estos res\u00famenes de lo m\u00e1s destacado del \u201c11th International Congress on Systematic Lupus Erythematosus\u201d, en Viena 2015 para Lupus Review. LUPUS REVIEW es una iniciativa de la Sociedad Espa\u00f1ola de Reumatolog\u00eda, que ha contado con la colaboraci\u00f3n de GSK. Estos v\u00eddeos [&hellip;]\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/lupusgalicia.org\/?p=1341\" \/>\r\n<meta property=\"og:site_name\" content=\"Asociaci\u00f3n Galega de Lupus\" \/>\r\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/LupusGalicia\/\" \/>\r\n<meta property=\"article:published_time\" content=\"2015-10-14T23:32:37+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2015-10-15T00:03:11+00:00\" \/>\r\n<meta name=\"author\" content=\"Agal\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:creator\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:site\" content=\"@LupusGalicia\" \/>\r\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Agal\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutos\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=1341#article\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=1341\"},\"author\":{\"name\":\"Agal\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\"},\"headline\":\"Lupus Viena 2015. Lupus Review\",\"datePublished\":\"2015-10-14T23:32:37+00:00\",\"dateModified\":\"2015-10-15T00:03:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=1341\"},\"wordCount\":1262,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"keywords\":[\"Congreso Internacional Lupus\",\"Congresos\",\"jornadas y congresos\",\"mujer l\u00fapica\",\"Nuevas mol\u00e9culas\"],\"articleSection\":[\"Jornadas y Congresos\",\"Lupus Internacional\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=1341#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=1341\",\"url\":\"https:\/\/lupusgalicia.org\/?p=1341\",\"name\":\"Lupus Viena 2015. Lupus Review - Asociaci\u00f3n Galega de Lupus\",\"isPartOf\":{\"@id\":\"https:\/\/lupusgalicia.org\/#website\"},\"datePublished\":\"2015-10-14T23:32:37+00:00\",\"dateModified\":\"2015-10-15T00:03:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/lupusgalicia.org\/?p=1341#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/lupusgalicia.org\/?p=1341\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/lupusgalicia.org\/?p=1341#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/lupusgalicia.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lupus Viena 2015. Lupus Review\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/lupusgalicia.org\/#website\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"description\":\"Trabajando para y por las personas con Lupus\",\"publisher\":{\"@id\":\"https:\/\/lupusgalicia.org\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/lupusgalicia.org\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/lupusgalicia.org\/#organization\",\"name\":\"Asociaci\u00f3n Galega de Lupus\",\"url\":\"https:\/\/lupusgalicia.org\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"contentUrl\":\"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png\",\"width\":2560,\"height\":2522,\"caption\":\"Asociaci\u00f3n Galega de Lupus\"},\"image\":{\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/LupusGalicia\/\",\"https:\/\/x.com\/LupusGalicia\",\"https:\/\/www.instagram.com\/lupusgalicia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665\",\"name\":\"Agal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g\",\"caption\":\"Agal\"},\"description\":\"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...\",\"sameAs\":[\"http:\/\/www.lupusgalicia.org\"],\"url\":\"https:\/\/lupusgalicia.org\/?author=1\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lupus Viena 2015. Lupus Review - Asociaci\u00f3n Galega de Lupus","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/lupusgalicia.org\/?p=1341","og_locale":"es_ES","og_type":"article","og_title":"Lupus Viena 2015. Lupus Review - Asociaci\u00f3n Galega de Lupus","og_description":"El Dr. Jaime Calvo Al\u00e9n,\u00a0experto en el \u00e1mbito de las enfermedades autoinmunes sist\u00e9micas ha realizado\u00a0estos res\u00famenes de lo m\u00e1s destacado del \u201c11th International Congress on Systematic Lupus Erythematosus\u201d, en Viena 2015 para Lupus Review. LUPUS REVIEW es una iniciativa de la Sociedad Espa\u00f1ola de Reumatolog\u00eda, que ha contado con la colaboraci\u00f3n de GSK. Estos v\u00eddeos [&hellip;]","og_url":"https:\/\/lupusgalicia.org\/?p=1341","og_site_name":"Asociaci\u00f3n Galega de Lupus","article_publisher":"https:\/\/www.facebook.com\/LupusGalicia\/","article_published_time":"2015-10-14T23:32:37+00:00","article_modified_time":"2015-10-15T00:03:11+00:00","author":"Agal","twitter_card":"summary_large_image","twitter_creator":"@LupusGalicia","twitter_site":"@LupusGalicia","twitter_misc":{"Escrito por":"Agal","Tiempo de lectura":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/lupusgalicia.org\/?p=1341#article","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/?p=1341"},"author":{"name":"Agal","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665"},"headline":"Lupus Viena 2015. Lupus Review","datePublished":"2015-10-14T23:32:37+00:00","dateModified":"2015-10-15T00:03:11+00:00","mainEntityOfPage":{"@id":"https:\/\/lupusgalicia.org\/?p=1341"},"wordCount":1262,"commentCount":0,"publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"keywords":["Congreso Internacional Lupus","Congresos","jornadas y congresos","mujer l\u00fapica","Nuevas mol\u00e9culas"],"articleSection":["Jornadas y Congresos","Lupus Internacional"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/lupusgalicia.org\/?p=1341#respond"]}]},{"@type":"WebPage","@id":"https:\/\/lupusgalicia.org\/?p=1341","url":"https:\/\/lupusgalicia.org\/?p=1341","name":"Lupus Viena 2015. Lupus Review - Asociaci\u00f3n Galega de Lupus","isPartOf":{"@id":"https:\/\/lupusgalicia.org\/#website"},"datePublished":"2015-10-14T23:32:37+00:00","dateModified":"2015-10-15T00:03:11+00:00","breadcrumb":{"@id":"https:\/\/lupusgalicia.org\/?p=1341#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/lupusgalicia.org\/?p=1341"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/lupusgalicia.org\/?p=1341#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/lupusgalicia.org\/"},{"@type":"ListItem","position":2,"name":"Lupus Viena 2015. Lupus Review"}]},{"@type":"WebSite","@id":"https:\/\/lupusgalicia.org\/#website","url":"https:\/\/lupusgalicia.org\/","name":"Asociaci\u00f3n Galega de Lupus","description":"Trabajando para y por las personas con Lupus","publisher":{"@id":"https:\/\/lupusgalicia.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/lupusgalicia.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/lupusgalicia.org\/#organization","name":"Asociaci\u00f3n Galega de Lupus","url":"https:\/\/lupusgalicia.org\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/","url":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","contentUrl":"https:\/\/lupusgalicia.org\/wp-content\/uploads\/2023\/06\/AGAL-scaled.png","width":2560,"height":2522,"caption":"Asociaci\u00f3n Galega de Lupus"},"image":{"@id":"https:\/\/lupusgalicia.org\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/LupusGalicia\/","https:\/\/x.com\/LupusGalicia","https:\/\/www.instagram.com\/lupusgalicia\/"]},{"@type":"Person","@id":"https:\/\/lupusgalicia.org\/#\/schema\/person\/4c5a48f33530bf5afca090219ff56665","name":"Agal","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7f60df48bf4a5a797270581c89811177b4ff71b18f397a910784a9bfc7025e33?s=96&d=mm&r=g","caption":"Agal"},"description":"AGAL. Asociaci\u00f3n Galega de Lupus. Creada en 1997. Pretendemos dar informaci\u00f3n sobre el Lupus y que la enfermedad deje de ser una gran desconocida; ayudar a familiares y amigos; promover investigaci\u00f3n; divulgar y relacionar a nuestros asociados a trav\u00e9s de Jornadas, la revista Papilio, charlas, reuniones...","sameAs":["http:\/\/www.lupusgalicia.org"],"url":"https:\/\/lupusgalicia.org\/?author=1"}]}},"_links":{"self":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/1341","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1341"}],"version-history":[{"count":6,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/1341\/revisions"}],"predecessor-version":[{"id":1347,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=\/wp\/v2\/posts\/1341\/revisions\/1347"}],"wp:attachment":[{"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1341"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1341"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lupusgalicia.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1341"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}